Mayne Pharma Group Ltd (ASX: MYX) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Mayne Pharma Group Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $270.24 million
P/E Ratio 8.46
Dividend Yield 0.00%
Shares Outstanding 81.89 million
Earnings per share 0.390
Dividend per share 0.04
Year To Date Return 6.11%
Earnings Yield 11.82%
Franking 100%
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Mayne Pharma Group Ltd (ASX: MYX)
    Latest News

    Investor looking at his phone with an idea with skyscrapers in the background.
    How to invest

    Australian billionaires: Which stocks do they own?

    Here are the top stock picks by Australia's wealthiest people.

    Read more »

    Man looking happy and excited as he looks at his mobile phone.
    Share Gainers

    Why Coronado, DroneShield, Lovisa, and Mayne Pharma shares are racing higher today

    These shares are having a good time on hump day. But why?

    Read more »

    A young man punches the air in delight as he reacts to great news on his mobile phone.
    Share Gainers

    Why ARB, Block, Mayne Pharma, and Paladin Energy shares are charging higher today

    These shares are having a strong finish to the week. But why?

    Read more »

    A man sits in despair at his computer with his hands either side of his head, staring into the screen with a pained and anguished look on his face, in a home office setting.
    Share Fallers

    Why Dexus, Mayne Pharma, Nufarm, and Treasury Wine shares are falling today

    These shares are having a tough session on Thursday. But why?

    Read more »

    A young man clasps his hand to his head with a pained expression on his face and a laptop in front of him.
    Share Fallers

    Why James Hardie, Mayne Pharma, Nufarm, and Resimac shares are falling today

    These shares are having a tough time on hump day. But why?

    Read more »

    A group of business people sit dejectedly around a table, each expressing desolation, sadness, and disappointment by holding their head in their hands, casting their gazes down and looking very glum.
    Mergers & Acquisitions

    This ASX 300 share is sinking 33% on takeover collapse fears

    Is this takeover dead? Let's find out what is happening.

    Read more »

    A woman jumps for joy with a rocket drawn on the wall behind her.
    Share Gainers

    Why Domain, Mayne Pharma, QBE, and Telix shares are jumping today

    These shares are ending the week with a bang. Here's why they are jumping.

    Read more »

    two men shake hands on a deal.
    Healthcare Shares

    Can you guess which ASX 300 healthcare stock is rocketing 34% on takeover news

    This share is rocketing on Friday after accepting a takeover offer.

    Read more »

    Two lab workers fist pump each other.
    Healthcare Shares

    Guess which ASX 300 healthcare stock just rocketed 20% on BIG earnings growth

    Investors are piling into the ASX 300 healthcare stock on Monday. But why?

    Read more »

    A young woman raises her hands in joyful celebration as she sits at her computer in a home environment.
    Share Gainers

    Why Ansell, GQG, Mayne Pharma, and Star shares are charging higher today

    These shares are starting the week on a positive note. But why?

    Read more »

    A women cheers with clenched fists having read some good news on her laptop.
    Share Gainers

    Why Bank of Queensland, Fisher & Paykel, Mayne Pharma, and Medibank shares are rising

    These shares are ending the week strongly. But why?

    Read more »

    Three health professionals at a hospital smile for the camera.
    Earnings Results

    3 ASX healthcare stocks surging after strong FY24 earnings

    These ASX healthcare stocks all came in with solid numbers in FY24.

    Read more »

    Frequently Asked Questions

    Mayne Pharma made a fully franked cash payment to shareholders in January 2023. Prior to that, the company’s last dividend payout was in 2011.

    Mayne Pharma Group Ltd listed on the ASX on 29 June 2007.

    Dividend Payment History Data provided by Morningstar.

    Data provided by Morningstar.
    Ex-Date Amount Franking Type Payable
    18 Jan 2023 $0.0272 100.00% Special Cash 27 Jan 2023

    MYX ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Mayne Pharma Group Ltd

    Mayne Pharma Group Ltd (ASX: MYX) is a specialty pharmaceutical company focused on commercialising branded and generic pharmaceutical products. Its South Australian manufacturing base produces a portfolio of oral and topical products including tablets, powders, capsules, liquids, and creams.

    Mayne Pharma performs limited research and development, typically acquiring off-patent or tail-end pharmaceutical brands. The company also has a contract manufacturing segment and advertises its services in assisting other drug developers in getting their products to market. The Group earns more than 90% of its revenue from the US market. 

    MYX Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    13 Nov 2026 $3.30 $-0.09 -2.65% 438,528 $3.34 $3.36 $3.29
    12 Nov 2026 $3.39 $0.03 0.89% 594,661 $3.34 $3.42 $3.29
    11 Nov 2026 $3.36 $-0.04 -1.18% 926,713 $3.31 $3.47 $3.28
    10 Nov 2026 $3.40 $0.13 3.98% 1,030,707 $3.30 $3.44 $3.28
    09 Nov 2026 $3.27 $0.19 6.17% 1,030,973 $3.07 $3.38 $3.04
    06 Nov 2026 $3.08 $0.37 13.65% 867,061 $2.72 $3.08 $2.67
    05 Nov 2026 $2.71 $0.09 3.44% 120,646 $2.62 $2.72 $2.61
    04 Nov 2026 $2.62 $0.03 1.16% 102,784 $2.60 $2.63 $2.56
    03 Nov 2026 $2.59 $0.05 1.97% 44,423 $2.54 $2.59 $2.53
    02 Nov 2026 $2.54 $0.00 0.00% 49,893 $2.58 $2.58 $2.51
    30 Oct 2026 $2.54 $0.04 1.60% 95,685 $2.53 $2.55 $2.48
    29 Oct 2026 $2.50 $-0.13 -4.94% 418,627 $2.65 $2.65 $2.46
    28 Oct 2026 $2.63 $0.21 8.68% 109,280 $2.45 $2.63 $2.44
    27 Oct 2026 $2.42 $-0.06 -2.42% 154,496 $2.45 $2.46 $2.40
    26 Oct 2026 $2.48 $0.03 1.22% 84,157 $2.55 $2.55 $2.45
    23 Oct 2026 $2.45 $-0.04 -1.61% 103,598 $2.47 $2.49 $2.42
    22 Oct 2026 $2.49 $-0.05 -1.97% 119,543 $2.54 $2.56 $2.49
    21 Oct 2026 $2.54 $0.00 0.00% 123,158 $2.55 $2.61 $2.53
    20 Oct 2026 $2.54 $-0.01 -0.39% 120,955 $2.55 $2.56 $2.52
    19 Oct 2026 $2.55 $0.03 1.19% 125,283 $2.52 $2.61 $2.52
    16 Oct 2026 $2.52 $0.03 1.20% 103,574 $2.50 $2.63 $2.50

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    18 Dec 2025 Shawn O'Brien Sell 129,736 $401,341
    On-market trade.
    18 Dec 2025 Shawn O'Brien Exercise 326,452 $989,149
    Conversion of securities. 641014 rights
    18 Dec 2025 Shawn O'Brien Buy 326,452 $989,149
    Conversion of securities.
    18 Dec 2025 Shawn O'Brien Expiry 72,821 $220,647
    As advised by the company. lapsed, 568193 Rights

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Professor Bruce Gregory Robinson AC Non-Executive DirectorNon-Executive Chairman Aug 2014
    Prof Robinson has been the head of the Cancer Genetics Unit at the Kolling Institute of Medical Research, Royal North Shore Hospital since 1989. Since 2001, he has been Chairman of Hoc Mai Foundation, a major program in medical and health education and exchange with Vietnam. He is the member of the risk committee.
    Ms Ann Custin Non-Executive Director Mar 2022
    Ms Custin, a US resident, has almost 40 years of experience in the healthcare sector. Most recently, Ms Custin was Board Director and CFO of Siemens Medical Solutions (now Siemens Healthineers), a medical technology company with EUR20b in revenues. Previously, she was Chief Operating and Financial Officer of Scient'x Group and President and CEO of USA Draeger Medical Systems. She is the chairperson of the risk committee and chairperson of the people committee.
    Mr David Petrie Non-Executive Director Sep 2022
    Mr Petrie is an M&A executive with over 30 years of advisory experience in public and private mergers and acquisitions, capital management and debt and equity raisings. Previously, he spent 23 years at Merrill Lynch/Bank of America including Managing Director and Head of Investment Banking Melbourne. He is the member of the risk committee and People Committee.
    Ms Meghan Rivera Non-Executive Director Jun 2026
    Ms Rivera, a US resident, has brought more than 25 years of experience in the US pharmaceutical industry across multiple therapeutic areas including women's health. Ms Rivera's experience includes building, developing and transforming businesses across biopharma, and she has played a role in launching branded products in the US. She is the member of the People Committee.
    Mr Jacob Haft Ma-Weaver Non-Executive Director Aug 2026
    Mr Ma-Weaver is the Managing Member of Cable Car Capital, LP (Cable Car), an investment adviser he founded in 2013. Mr Ma-Weaver served on the Board of ARCA biopharma, Inc. from 2022 until its business combination with Oruka Therapeutics in 2024. Mr Ma-Weaver worked as an equity research associate at Dodge & Cox and a corporate finance business analyst at McKinsey & Company.
    Ms Laura Loftus Company Secretary Mar 2020
    -
    Laura Loftus Company Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Citicorp Nominees Pty Limited 8,310,352 10.23%
    BNP Paribas Nominees Pty Ltd <Ib Au Nomis Retailclient> 7,932,142 9.76%
    HSBC Custody Nominees (Australia) Limited A/C 2 5,409,304 6.66%
    BMG B J Myx Pty Ltd <Bmgbj Myx Discretionary A/C> 5,183,477 6.38%
    HSBC Custody Nominees (Australia) Limited <Gsco Customers A/C> 4,457,159 5.49%
    BNP Paribas Nominees Pty Ltd <Cowen And Co Llc> 2,406,601 2.96%
    HSBC Custody Nominees (Australia) Limited 2,298,086 2.83%
    Warbont Nominees Pty Ltd <Unpaid Entrepot A/C> 2,014,093 2.48%
    BNP Paribas Noms Pty Ltd 1,496,245 1.84%
    Dr Kenney Wan 1,355,391 1.67%
    J P Morgan Nominees Australia Pty Limited 1,275,296 1.57%
    Boardroom Financial Services Pty Limited <Vsa Unrestricted A/C> 1,240,877 1.53%
    Birbal Investments Pty Ltd 950,000 1.17%
    IVL Group Pty Ltd 800,000 0.98%
    Triple Eight Gold Pty Ltd <The Blue Sky A/C> 760,856 0.94%
    Narlack Pty Ltd <Pipergolou Pension A/C> 720,000 0.89%
    Rmk Super Pty Ltd <Rmk Personal S/F A/C> 713,788 0.88%
    Mr Kon Tzimokas 643,000 0.79%
    Retzos Executive Pty Ltd <Retzos Executive S/Fund A/C> 596,049 0.73%
    Morgan Stanley Australia Securities (Nominee) Pty Limited <No 1 Account> 547,397 0.67%

    Profile

    since

    Note